[{"edinetCode":"E00947","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1713.0,"averageTemporaryStaff":418.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8459000.0,"sharesOwendPercent":0.4123,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":5634.73,"equityRatio":0.754,"cashAndCashEquivalents":30808000000.0,"assets":148372000000.0,"currentAssets":112016000000.0,"fixedAsset":36356000000.0,"tangibleFixedAssets":15009000000.0,"intangibleFixedAssets":410000000.0,"investmentAndOtherAssets":20935000000.0,"liabilities":36502000000.0,"currentLiabilities":30269000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":6233000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":111869000000.0,"capitalStock":105792000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":100040000000.0,"treasuryStock":-3349000000.0,"valuationAndConversionAdjustments":6076000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":97349000000.0,"costOfSales":41043000000.0,"grossProfit":56306000000.0,"sgaExpenses":44936000000.0,"salaryAndBenefit":7205000000.0,"depreciationAndSGA":null,"RDExpenses":15226000000.0,"operatingIncome":11374000000.0,"nonOperatingIncome":340000000.0,"nonOperatingExpenses":66000000.0,"interestExpense":10000000.0,"ordinaryProfit":11648000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":64000000.0,"incomeBeforeTax":11583000000.0,"incomeTaxes":3057000000.0,"netIncome":8526000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":8526000000.0,"comprehensiveIncome":9686000000.0,"eps":429.46,"dilutedEps":null,"dividendPerShare":null,"per":19.2,"roe":0.079,"cashFlowFromOperatingActivities":5583000000.0,"depreciationAndCashflowFromOperatingActivities":2734000000.0,"cashFlowFromInvestingActivities":-1835000000.0,"cashFlowFromFinancialActivities":-3291000000.0,"changesInCashAndCashEquivalents":456000000.0,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4534,"accountingYear":"第79期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1666.0,"averageTemporaryStaff":420.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8539000.0,"sharesOwendPercent":0.4302,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":6029.05,"equityRatio":0.772,"cashAndCashEquivalents":30182000000.0,"assets":155054000000.0,"currentAssets":116302000000.0,"fixedAsset":38751000000.0,"tangibleFixedAssets":13915000000.0,"intangibleFixedAssets":365000000.0,"investmentAndOtherAssets":24470000000.0,"liabilities":35367000000.0,"currentLiabilities":29574000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5793000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":119687000000.0,"capitalStock":111376000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":104625000000.0,"treasuryStock":-2349000000.0,"valuationAndConversionAdjustments":8310000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":106761000000.0,"costOfSales":53182000000.0,"grossProfit":53578000000.0,"sgaExpenses":41904000000.0,"salaryAndBenefit":7334000000.0,"depreciationAndSGA":null,"RDExpenses":11912000000.0,"operatingIncome":11662000000.0,"nonOperatingIncome":392000000.0,"nonOperatingExpenses":46000000.0,"interestExpense":3000000.0,"ordinaryProfit":12008000000.0,"extraordinaryGain":194000000.0,"extraordinaryLoss":86000000.0,"incomeBeforeTax":12116000000.0,"incomeTaxes":3092000000.0,"netIncome":9023000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":9023000000.0,"comprehensiveIncome":11257000000.0,"eps":454.55,"dilutedEps":null,"dividendPerShare":null,"per":16.5,"roe":0.078,"cashFlowFromOperatingActivities":3283000000.0,"depreciationAndCashflowFromOperatingActivities":2618000000.0,"cashFlowFromInvestingActivities":-426000000.0,"cashFlowFromFinancialActivities":-3483000000.0,"changesInCashAndCashEquivalents":-625000000.0,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4534,"accountingYear":"第80期(自　2017年４月１日　至　2018年３月31日)","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1617.0,"averageTemporaryStaff":448.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8797000.0,"sharesOwendPercent":0.4485,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":3189.15,"equityRatio":0.787,"cashAndCashEquivalents":35532000000.0,"assets":159019000000.0,"currentAssets":115334000000.0,"fixedAsset":43685000000.0,"tangibleFixedAssets":13589000000.0,"intangibleFixedAssets":372000000.0,"investmentAndOtherAssets":29723000000.0,"liabilities":33909000000.0,"currentLiabilities":28444000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5465000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":125110000000.0,"capitalStock":113767000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":109537000000.0,"treasuryStock":-4870000000.0,"valuationAndConversionAdjustments":11342000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":109643000000.0,"costOfSales":55477000000.0,"grossProfit":54166000000.0,"sgaExpenses":43584000000.0,"salaryAndBenefit":7185000000.0,"depreciationAndSGA":null,"RDExpenses":13003000000.0,"operatingIncome":10590000000.0,"nonOperatingIncome":408000000.0,"nonOperatingExpenses":71000000.0,"interestExpense":1000000.0,"ordinaryProfit":10928000000.0,"extraordinaryGain":1850000000.0,"extraordinaryLoss":1135000000.0,"incomeBeforeTax":11642000000.0,"incomeTaxes":3207000000.0,"netIncome":8435000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":8435000000.0,"comprehensiveIncome":11467000000.0,"eps":212.87,"dilutedEps":null,"dividendPerShare":null,"per":26.7,"roe":0.069,"cashFlowFromOperatingActivities":12565000000.0,"depreciationAndCashflowFromOperatingActivities":2917000000.0,"cashFlowFromInvestingActivities":-1121000000.0,"cashFlowFromFinancialActivities":-6094000000.0,"changesInCashAndCashEquivalents":5349000000.0,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4534,"accountingYear":"第81期(自　2018年4月1日　至　2019年3月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.792,"cashAndCashEquivalents":null,"assets":156905000000.0,"currentAssets":116003000000.0,"fixedAsset":40901000000.0,"tangibleFixedAssets":13389000000.0,"intangibleFixedAssets":450000000.0,"investmentAndOtherAssets":27062000000.0,"liabilities":32641000000.0,"currentLiabilities":27245000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5396000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":124263000000.0,"capitalStock":115304000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":111076000000.0,"treasuryStock":-4874000000.0,"valuationAndConversionAdjustments":8959000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":26488000000.0,"costOfSales":12351000000.0,"grossProfit":14137000000.0,"sgaExpenses":9614000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":4519000000.0,"nonOperatingIncome":165000000.0,"nonOperatingExpenses":18000000.0,"interestExpense":null,"ordinaryProfit":4666000000.0,"extraordinaryGain":5000000.0,"extraordinaryLoss":1000000.0,"incomeBeforeTax":4670000000.0,"incomeTaxes":1365000000.0,"netIncome":3305000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3305000000.0,"comprehensiveIncome":921000000.0,"eps":84.25,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4534,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":17647000.0,"sharesOwendPercent":0.4499,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.812,"cashAndCashEquivalents":35859000000.0,"assets":154692000000.0,"currentAssets":113673000000.0,"fixedAsset":41019000000.0,"tangibleFixedAssets":13424000000.0,"intangibleFixedAssets":715000000.0,"investmentAndOtherAssets":26879000000.0,"liabilities":29072000000.0,"currentLiabilities":23713000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5358000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":125619000000.0,"capitalStock":116589000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":112364000000.0,"treasuryStock":-4876000000.0,"valuationAndConversionAdjustments":9030000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":51512000000.0,"costOfSales":24915000000.0,"grossProfit":26597000000.0,"sgaExpenses":20390000000.0,"salaryAndBenefit":3605000000.0,"depreciationAndSGA":null,"RDExpenses":4943000000.0,"operatingIncome":6200000000.0,"nonOperatingIncome":205000000.0,"nonOperatingExpenses":11000000.0,"interestExpense":null,"ordinaryProfit":6393000000.0,"extraordinaryGain":8000000.0,"extraordinaryLoss":35000000.0,"incomeBeforeTax":6366000000.0,"incomeTaxes":1774000000.0,"netIncome":4592000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4592000000.0,"comprehensiveIncome":2280000000.0,"eps":117.07,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":1908000000.0,"depreciationAndCashflowFromOperatingActivities":1317000000.0,"cashFlowFromInvestingActivities":192000000.0,"cashFlowFromFinancialActivities":-1773000000.0,"changesInCashAndCashEquivalents":327000000.0,"列1":"q2r","submitDate":"2019\/11\/12","stockCode":4534,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.796,"cashAndCashEquivalents":null,"assets":157409000000.0,"currentAssets":115727000000.0,"fixedAsset":41682000000.0,"tangibleFixedAssets":13546000000.0,"intangibleFixedAssets":705000000.0,"investmentAndOtherAssets":27431000000.0,"liabilities":32077000000.0,"currentLiabilities":26774000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5303000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":125332000000.0,"capitalStock":115804000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":112580000000.0,"treasuryStock":-5878000000.0,"valuationAndConversionAdjustments":9528000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":79097000000.0,"costOfSales":38269000000.0,"grossProfit":40827000000.0,"sgaExpenses":32466000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":8353000000.0,"nonOperatingIncome":367000000.0,"nonOperatingExpenses":66000000.0,"interestExpense":null,"ordinaryProfit":8655000000.0,"extraordinaryGain":8000000.0,"extraordinaryLoss":41000000.0,"incomeBeforeTax":8622000000.0,"incomeTaxes":2244000000.0,"netIncome":6378000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6378000000.0,"comprehensiveIncome":4563000000.0,"eps":162.74,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/13","stockCode":4534,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1581.0,"averageTemporaryStaff":482.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":17686000.0,"sharesOwendPercent":0.4564,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":3113.69,"equityRatio":0.766,"cashAndCashEquivalents":37791000000.0,"assets":157488000000.0,"currentAssets":116894000000.0,"fixedAsset":40593000000.0,"tangibleFixedAssets":13851000000.0,"intangibleFixedAssets":674000000.0,"investmentAndOtherAssets":26067000000.0,"liabilities":36822000000.0,"currentLiabilities":28562000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8260000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":120665000000.0,"capitalStock":113047000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":110800000000.0,"treasuryStock":-6854000000.0,"valuationAndConversionAdjustments":7617000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":101799000000.0,"costOfSales":49882000000.0,"grossProfit":51917000000.0,"sgaExpenses":43112000000.0,"salaryAndBenefit":7254000000.0,"depreciationAndSGA":null,"RDExpenses":11884000000.0,"operatingIncome":8807000000.0,"nonOperatingIncome":413000000.0,"nonOperatingExpenses":65000000.0,"interestExpense":null,"ordinaryProfit":9154000000.0,"extraordinaryGain":195000000.0,"extraordinaryLoss":3077000000.0,"incomeBeforeTax":6273000000.0,"incomeTaxes":1675000000.0,"netIncome":4598000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4598000000.0,"comprehensiveIncome":873000000.0,"eps":117.56,"dilutedEps":null,"dividendPerShare":null,"per":35.5,"roe":0.037,"cashFlowFromOperatingActivities":9347000000.0,"depreciationAndCashflowFromOperatingActivities":2731000000.0,"cashFlowFromInvestingActivities":-1760000000.0,"cashFlowFromFinancialActivities":-5328000000.0,"changesInCashAndCashEquivalents":2259000000.0,"列1":"asr","submitDate":"2020\/6\/26","stockCode":4534,"accountingYear":"第82期(自　2019年4月1日　至　2020年3月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.785,"cashAndCashEquivalents":null,"assets":157039000000.0,"currentAssets":114997000000.0,"fixedAsset":42042000000.0,"tangibleFixedAssets":13681000000.0,"intangibleFixedAssets":635000000.0,"investmentAndOtherAssets":27725000000.0,"liabilities":33738000000.0,"currentLiabilities":25465000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8272000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":123301000000.0,"capitalStock":114863000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":112617000000.0,"treasuryStock":-6855000000.0,"valuationAndConversionAdjustments":8437000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":27379000000.0,"costOfSales":12979000000.0,"grossProfit":14400000000.0,"sgaExpenses":9804000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":4594000000.0,"nonOperatingIncome":165000000.0,"nonOperatingExpenses":23000000.0,"interestExpense":null,"ordinaryProfit":4736000000.0,"extraordinaryGain":27000000.0,"extraordinaryLoss":0.0,"incomeBeforeTax":4762000000.0,"incomeTaxes":1395000000.0,"netIncome":3367000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3367000000.0,"comprehensiveIncome":4186000000.0,"eps":86.89,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/7","stockCode":4534,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18030000.0,"sharesOwendPercent":0.4653,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.793,"cashAndCashEquivalents":38323000000.0,"assets":158480000000.0,"currentAssets":116361000000.0,"fixedAsset":42118000000.0,"tangibleFixedAssets":13632000000.0,"intangibleFixedAssets":669000000.0,"investmentAndOtherAssets":27817000000.0,"liabilities":32803000000.0,"currentLiabilities":24582000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8220000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":125677000000.0,"capitalStock":116907000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":114661000000.0,"treasuryStock":-6856000000.0,"valuationAndConversionAdjustments":8769000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":51623000000.0,"costOfSales":24491000000.0,"grossProfit":27132000000.0,"sgaExpenses":19902000000.0,"salaryAndBenefit":3551000000.0,"depreciationAndSGA":null,"RDExpenses":4651000000.0,"operatingIncome":7229000000.0,"nonOperatingIncome":194000000.0,"nonOperatingExpenses":38000000.0,"interestExpense":null,"ordinaryProfit":7385000000.0,"extraordinaryGain":27000000.0,"extraordinaryLoss":59000000.0,"incomeBeforeTax":7353000000.0,"incomeTaxes":1942000000.0,"netIncome":5411000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":5411000000.0,"comprehensiveIncome":6563000000.0,"eps":139.63,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":3013000000.0,"depreciationAndCashflowFromOperatingActivities":1309000000.0,"cashFlowFromInvestingActivities":-925000000.0,"cashFlowFromFinancialActivities":-1553000000.0,"changesInCashAndCashEquivalents":531000000.0,"列1":"q2r","submitDate":"2020\/11\/12","stockCode":4534,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.777,"cashAndCashEquivalents":null,"assets":160584000000.0,"currentAssets":119885000000.0,"fixedAsset":40698000000.0,"tangibleFixedAssets":13513000000.0,"intangibleFixedAssets":678000000.0,"investmentAndOtherAssets":26506000000.0,"liabilities":35793000000.0,"currentLiabilities":29588000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":6205000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":124790000000.0,"capitalStock":117353000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":116108000000.0,"treasuryStock":-7856000000.0,"valuationAndConversionAdjustments":7437000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":79881000000.0,"costOfSales":36933000000.0,"grossProfit":42948000000.0,"sgaExpenses":31755000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":11184000000.0,"nonOperatingIncome":351000000.0,"nonOperatingExpenses":108000000.0,"interestExpense":null,"ordinaryProfit":11428000000.0,"extraordinaryGain":32000000.0,"extraordinaryLoss":197000000.0,"incomeBeforeTax":11263000000.0,"incomeTaxes":2855000000.0,"netIncome":8407000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":8407000000.0,"comprehensiveIncome":8227000000.0,"eps":217.19,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/12","stockCode":4534,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1558.0,"averageTemporaryStaff":504.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":18097000.0,"sharesOwendPercent":0.4729,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":3317.92,"equityRatio":0.785,"cashAndCashEquivalents":40987000000.0,"assets":161791000000.0,"currentAssets":118793000000.0,"fixedAsset":42998000000.0,"tangibleFixedAssets":13299000000.0,"intangibleFixedAssets":646000000.0,"investmentAndOtherAssets":29051000000.0,"liabilities":34816000000.0,"currentLiabilities":28710000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":6106000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":126974000000.0,"capitalStock":116532000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":116288000000.0,"treasuryStock":-8857000000.0,"valuationAndConversionAdjustments":10442000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":102995000000.0,"costOfSales":48203000000.0,"grossProfit":54791000000.0,"sgaExpenses":42788000000.0,"salaryAndBenefit":7161000000.0,"depreciationAndSGA":null,"RDExpenses":10849000000.0,"operatingIncome":12003000000.0,"nonOperatingIncome":405000000.0,"nonOperatingExpenses":148000000.0,"interestExpense":null,"ordinaryProfit":12260000000.0,"extraordinaryGain":35000000.0,"extraordinaryLoss":395000000.0,"incomeBeforeTax":11900000000.0,"incomeTaxes":3312000000.0,"netIncome":8587000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":8587000000.0,"comprehensiveIncome":11412000000.0,"eps":222.29,"dilutedEps":null,"dividendPerShare":null,"per":19.3,"roe":0.069,"cashFlowFromOperatingActivities":9198000000.0,"depreciationAndCashflowFromOperatingActivities":2742000000.0,"cashFlowFromInvestingActivities":-880000000.0,"cashFlowFromFinancialActivities":-5112000000.0,"changesInCashAndCashEquivalents":3195000000.0,"列1":"asr","submitDate":"2021\/6\/29","stockCode":4534,"accountingYear":"第83期(自　2020年4月1日　至　2021年3月31日)","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.786,"cashAndCashEquivalents":null,"assets":162244000000.0,"currentAssets":119874000000.0,"fixedAsset":42370000000.0,"tangibleFixedAssets":13114000000.0,"intangibleFixedAssets":665000000.0,"investmentAndOtherAssets":28590000000.0,"liabilities":34738000000.0,"currentLiabilities":28666000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":6072000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":127505000000.0,"capitalStock":117270000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":117028000000.0,"treasuryStock":-8859000000.0,"valuationAndConversionAdjustments":10234000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":27362000000.0,"costOfSales":12406000000.0,"grossProfit":14956000000.0,"sgaExpenses":11772000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3183000000.0,"nonOperatingIncome":190000000.0,"nonOperatingExpenses":7000000.0,"interestExpense":null,"ordinaryProfit":3366000000.0,"extraordinaryGain":526000000.0,"extraordinaryLoss":76000000.0,"incomeBeforeTax":3816000000.0,"incomeTaxes":1162000000.0,"netIncome":2653000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2653000000.0,"comprehensiveIncome":2445000000.0,"eps":69.35,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/6","stockCode":4534,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":19361000.0,"sharesOwendPercent":0.5059,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.794,"cashAndCashEquivalents":41299000000.0,"assets":162357000000.0,"currentAssets":120390000000.0,"fixedAsset":41966000000.0,"tangibleFixedAssets":13786000000.0,"intangibleFixedAssets":651000000.0,"investmentAndOtherAssets":27529000000.0,"liabilities":33435000000.0,"currentLiabilities":27403000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":6031000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":128921000000.0,"capitalStock":119532000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":119291000000.0,"treasuryStock":-8860000000.0,"valuationAndConversionAdjustments":9389000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":54009000000.0,"costOfSales":25079000000.0,"grossProfit":28929000000.0,"sgaExpenses":22797000000.0,"salaryAndBenefit":3526000000.0,"depreciationAndSGA":null,"RDExpenses":6508000000.0,"operatingIncome":6131000000.0,"nonOperatingIncome":257000000.0,"nonOperatingExpenses":12000000.0,"interestExpense":null,"ordinaryProfit":6377000000.0,"extraordinaryGain":526000000.0,"extraordinaryLoss":110000000.0,"incomeBeforeTax":6793000000.0,"incomeTaxes":1876000000.0,"netIncome":4916000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4916000000.0,"comprehensiveIncome":3863000000.0,"eps":128.47,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":2891000000.0,"depreciationAndCashflowFromOperatingActivities":1318000000.0,"cashFlowFromInvestingActivities":-666000000.0,"cashFlowFromFinancialActivities":-1915000000.0,"changesInCashAndCashEquivalents":312000000.0,"列1":"q2r","submitDate":"2021\/11\/12","stockCode":4534,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0},{"edinetCode":"E00947","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.785,"cashAndCashEquivalents":null,"assets":164991000000.0,"currentAssets":124478000000.0,"fixedAsset":40513000000.0,"tangibleFixedAssets":13738000000.0,"intangibleFixedAssets":664000000.0,"investmentAndOtherAssets":26109000000.0,"liabilities":35445000000.0,"currentLiabilities":30478000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":4966000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":129546000000.0,"capitalStock":122424000000.0,"capital":7229000000.0,"capitalSurplus":1871000000.0,"accumulatedEarnings":123024000000.0,"treasuryStock":-9702000000.0,"valuationAndConversionAdjustments":7121000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":84814000000.0,"costOfSales":37985000000.0,"grossProfit":46829000000.0,"sgaExpenses":33783000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":13045000000.0,"nonOperatingIncome":440000000.0,"nonOperatingExpenses":39000000.0,"interestExpense":null,"ordinaryProfit":13447000000.0,"extraordinaryGain":526000000.0,"extraordinaryLoss":215000000.0,"incomeBeforeTax":13757000000.0,"incomeTaxes":3577000000.0,"netIncome":10180000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":10180000000.0,"comprehensiveIncome":6859000000.0,"eps":266.29,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/14","stockCode":4534,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00947","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":7229,"settlementDate":"2022\/3\/31","submitterName":"持田製薬株式会社","submitterNameEnglish":"Mochida Pharmaceutical Co.,Ltd.","submitterNameKana":"モチダセイヤクカブシキガイシャ","location":"新宿区四谷一丁目７番地","industory":"医薬品","corporateNumber":9010000000000.0}]